Unlocking the Power of Ino-3107

Groundbreaking Study Reveals 50% of RRP Patients Achieved Complete Response After 2-3 Years of Treatment

Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients who met the criteria for a Complete Response (CR) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial. 95% of patients in the retrospective trial (RRP-002) maintained or enhanced their original Overall Response Rate (ORR) reported in the Phase 1/2 trial (RRP-001) by the end of year 2; 86% of patients maintained or enhanced ORR into year 3. New durability data will help inform re-dosing strategy focused on long-term elimination or reduction in the need for surgery to treat RRP disease. INOVIO plans to present data at future scientific conferences and submit for publication in peer-reviewed journals.

How Will This Affect Me?

If you have been diagnosed with Recurrent Respiratory Papillomatosis (RRP), this groundbreaking study may offer a new treatment option that could potentially increase the chances of achieving a complete response and reducing the need for surgery in the long run. The new data provides hope for improved outcomes and better management of the disease.

How Will This Affect the World?

The findings from this study have the potential to have a significant impact on the world by providing a more effective treatment option for patients with RRP. By increasing the number of patients achieving a complete response and maintaining or enhancing their overall response rate, this could lead to better outcomes, reduced healthcare costs, and improved quality of life for individuals worldwide affected by this condition.

Conclusion

The data from the retrospective trial evaluating the longer-term benefit of INO-3107 in patients with Recurrent Respiratory Papillomatosis is promising and signifies a significant advancement in the treatment of this condition. The increased number of patients achieving a complete response and maintaining or enhancing their overall response rate is a positive step towards improving outcomes and reducing the need for surgical interventions. This study has the potential to impact the lives of individuals with RRP globally and pave the way for better management and treatment options in the future.